NCT00703547

A First Time in Human Study of GSK586529 in Healthy Volunteers

A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

A single blind, randomized, placebo-controlled, crossover study in twenty four healthy male subjects. Subjects will be divided into two cohorts with alternate panel design. The study is investigating the safety, tolerability and pharmacokinetics of single oral escalating doses of GSK586529.

Conditions

• Depressive Disorder and Anxiety Disorders

Interventions

Type	Name	Description
DRUG	GSK586529 capsules	GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
DRUG	GSK586529 tablets	GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
DRUG	Placebo	Placebo tablets and capsules will be provided to subjects.

Timeline

• Start date: 2008-01-28
• Primary completion: 2008-04-11
• Completion: 2008-04-11
• First posted: 2008-06-23
• Last updated: 2017-08-22

Locations

1 site across 1 country: United Kingdom